The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load

Clinical and Experimental Immunology

Volumn 181, Issue 3, 2015, Pages 457-467

  Egge, Kjetil H ^a   Barratt Due, Andreas ^a   Nymo, Stig ^b   Lindstad, Julie K ^a   Pharo, Anne ^a   Lau, Corinna ^b   Espevik, Terje ^c   Thorgersen, Ebbe B ^a   Mollnes, Tom E ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

CD14; Complement; Inflammation; Sepsis

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPSTATIN; ECULIZUMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; CYCLOPEPTIDE; CYTOKINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL LOAD; BLOOD; COMPLEMENT SYSTEM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RESPONSE; ESCHERICHIA COLI; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; ANTAGONISTS AND INHIBITORS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAT; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD11B; ANTIGENS, CD14; BACTERIAL LOAD; COMPLEMENT C3; COMPLEMENT C5; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; GRANULOCYTES; HOT TEMPERATURE; HUMANS; INFLAMMATION; MONOCYTES; PEPTIDES, CYCLIC; STAPHYLOCOCCUS AUREUS;

EID: 84939267589     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12645     Document Type: Article

References (40)

1. Kumar G, Kumar N, Taneja A et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011; 140:1223-31.
2. Levy MM, Dellinger RP, Townsend SR et al. The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intens Care Med 2010; 36:222-31.
3. Williams SC. After Xigris, researchers look to new targets to combat sepsis. Nat Med 2012; 18:1001.
4. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10:826-37.
5. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449:819-26.
6. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-5.
7. Kohl J. The role of complement in danger sensing and transmission. Immunol Res 2006; 34:157-76.
8. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-97.
9. Sarma JV, Ward PA. The complement system. Cell Tissue Res 2011; 343:227-35.
10. Ward PA. The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2010; 2:439-45.
11. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol 2012; 12:168-79.
12. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8.
13. Schroder NW, Morath S, Alexander C et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003; 278:15587-94.
14. Pietrocola G, Arciola CR, Rindi S et al. Toll-like receptors (TLRs) in innate immune defense against Staphylococcus aureus. Int J Artif Organs 2011; 34:799-810.
15. Nilsen NJ, Deininger S, Nonstad U et al. Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling: role of CD14 and CD36. J Leukoc Biol 2008; 84:280-91.
16. Hajishengallis G, Lambris JD. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 2010; 31:154-63.
17. Egge KH, Thorgersen EB, Lindstad JK et al. Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood. Innate Immun 2014; 20:68-77.
18. Lau C, Gunnarsen KS, Hoydahl LS et al. Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation. J Immunol 2013; 191:4769-77.
19. Qu H, Ricklin D, Bai H et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2013; 218:496-505.
20. Mollnes TE, Brekke OL, Fung M et al. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100:1869-77.
21. Lappegard KT, Christiansen D, Pharo A et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci USA 2009; 106:15861-6.
22. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22:197-202.
23. Mollnes TE, Redl H, Hogasen K et al. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993; 91:295-300.
24. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol 2013; 56:232-9.
25. Chaudhry H, Zhou J, Zhong Y et al. Role of cytokines as a double-edged sword in sepsis. In Vivo 2013; 27:669-84.
26. Hellerud BC, Stenvik J, Espevik T, Lambris JD, Mollnes TE, Brandtzaeg P. Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation. Infect Immun 2008; 76:4183-9.
27. Opal SM. Endotoxins and other sepsis triggers. Contrib Nephrol 2010; 167:14-24.
28. Skjeflo EW, Christiansen D, Espevik T, Nielsen EW, Mollnes TE. Combined inhibition of complement and CD14 efficiently attenuated the inflammatory response induced by Staphylococcus aureus in a human whole blood model. J Immunol 2014; 192:2857-64.
29. Baumann CL, Aspalter IM, Sharif O et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010; 207:2689-701.
30. Stoneking LR, Patanwala AE, Winkler JP et al. Would earlier microbe identification alter antibiotic therapy in bacteremic emergency department patients? J Emerg Med 2013; 44:1-8.
31. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170:1435-44.
32. Huber-Lang M, Barratt-Due A, Pischke SE et al. Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. J Immunol 2014; 192:5324-31.
33. Mera S, Tatulescu D, Cismaru C et al. Multiplex cytokine profiling in patients with sepsis. APMIS 2011; 119:155-63.
34. Wu HP, Chen CK, Chung K et al. Serial cytokine levels in patients with severe sepsis. Inflamm Res 2009; 58:385-93.
35. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009; 37:291-304.
36. Abraham E, Laterre PF, Garbino J et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1, 342 patients. Crit Care Med 2001; 29:503-10.
37. Fisher CJ Jr, Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-43.
38. Opal SM, Fisher CJ Jr, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-24.
39. Ember JA, Sanderson SD, Hugli TE, Morgan EL. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol 1994; 144:393-403.
40. Song WC. Crosstalk between complement and toll-like receptors. Toxicol Pathol 2012; 40:174-82.